Post by: Rajot on December 06, 2025, 10:54:15 PM
Biocon has announced a bold step in the biopharmaceutical landscape by merging its biosimilars division, Biocon Biologics, into the parent organization for $5.5 billion. This ambitious strategy is designed to streamline operations and amplify its influence across global markets, especially in diabetes care, cancer treatment, and immune therapies.Source: Biocon to merge biologics unit in $5.5 billion deal (https://timesofindia.indiatimes.com/india/biocon-to-merge-biologics-unit-in-5-5-billion-deal/articleshow/125809572.cms)